Limpid Markets
← Back to Intelligence

ROVI cuts 2026 revenue guidance on lower pharma demand

Investing.com Gold Tier 2 2026-05-06 07:24 UTC 📖 1 min read Neutral

Investing.com Gold reports: ROVI cuts 2026 revenue guidance on lower pharma demand. Full body text was unavailable at ingest time, so this brief is based on headline context.

↗ Read Original